Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

465
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
465
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

354
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
354
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

558
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
558
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

538
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
538
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intra-coronary imaging and transcriptomics of calcified nodules before and after intensive lipid-lowering therapy: a YELLOW III substudy.

European heart journal. Imaging methods and practice·2026
Same author

Restoration of Limb Alignment in Post-Traumatic Genu Varum Case Using Medial Open Wedge Proximal Tibial Osteotomy with Posterior Tibial Slope Correction: A Case Report.

Journal of orthopaedic case reports·2026
Same author

Standard modifiable risk factors among patients undergoing percutaneous coronary intervention: prevalence and impact.

European heart journal·2026
Same author

TOPSIS-Based Performance and Drilling Delamination Assessment of Chemically Treated PALF Composites for Lightweight UAVs.

ACS omega·2026
Same author

The Electrophysiology Experience in Patients With Ebstein's Anomaly Undergoing the da Silva Cone Repair at UPMC Children's Hospital of Pittsburgh.

Journal of cardiovascular electrophysiology·2026
Same author

Association of Proteinuria With Disease Stage and Treatment Response in Patients With Lymphoma: A Prospective Cohort Study.

Cureus·2026

Related Experiment Video

Updated: Mar 7, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K

Drug-Coated Balloons Beyond In-Stent Restenosis.

Rahul Gupta1, Chandrashekar Bohra2, Krishna Santosh Vemuri3

  • 1Department of General Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Reviews in Cardiovascular Medicine
|March 6, 2026
PubMed
Summary
This summary is machine-generated.

Drug-coated balloons (DCBs) offer a promising stent-free alternative in interventional cardiology. Evidence supports their use for various coronary lesions, potentially reducing risks associated with stents.

Keywords:
drug-coated balloondrug-eluting balloondrug-eluting stentdual antiplatelet therapy

More Related Videos

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.6K
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

17.1K

Related Experiment Videos

Last Updated: Mar 7, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K
A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.6K
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

17.1K

Area of Science:

  • Interventional Cardiology
  • Cardiovascular Devices

Background:

  • Drug-coated balloons (DCBs) are increasingly recognized for their therapeutic potential in interventional cardiology.
  • Existing evidence from trials and meta-analyses supports DCBs as a stent-free alternative for coronary lesions.
  • DCBs aim to mitigate risks like stent thrombosis and in-stent restenosis (ISR), and facilitate shorter dual antiplatelet therapy for high-bleeding-risk (HBR) patients.

Purpose of the Study:

  • To provide a comprehensive review of drug-coated balloon (DCB) therapy.
  • To explore the evolving role and expanding indications of DCBs beyond in-stent restenosis (ISR).

Main Methods:

  • Review of randomized trials, observational studies, and meta-analyses.
  • Analysis of clinical evidence supporting DCB efficacy.
  • Assessment of DCB applications in diverse coronary lesion types.

Main Results:

  • DCBs demonstrate efficacy across a wide range of coronary lesions.
  • DCBs present a viable alternative to conventional stenting strategies.
  • Emerging evidence supports DCB use in de novo lesions, bifurcation disease, HBR patients, and acute coronary syndromes.

Conclusions:

  • Drug-coated balloons (DCBs) are a significant advancement in interventional cardiology.
  • DCBs offer a valuable stent-free option with expanding clinical applications.
  • Further research and clinical adoption are expected for DCB therapy beyond ISR.